Skip to content

Platform trial in COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity and reactogenicity of licensed COVID-19 booster vaccines in immunocompetent individuals >12 years old. Here, we present data for seven different vaccines among three pre-specified participant strata defined by age and primary vaccine schedule.

Citation:
McLeod C, Dymock M, Flanagan KL, ……. Estcourt MJ, Tjiam MC, Blyth CC, Subbarao K, ……. Wadia U, Thornton RB, Tansil S, Tedja C, Ellis Z, Williams PCM, McKenzie A, Marsh JA, McCallum C, Snelling TL, Richmond P. The Platform trial inCOVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults. Vaccine. 2026;88.

Keywords:
Adaptive; COVID-19; Clinical trial; Humoral immunity; Vaccine

Abstract:
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity and reactogenicity of licensed COVID-19 booster vaccines in immunocompetent individuals >12 years old. Here, we present data for seven different vaccines among three pre-specified participant strata defined by age and primary vaccine schedule.